BIIB: pipeline progress and disciplined capital allocation highlighted
BIIB management cited diversification beyond neurology and pipeline momentum, including ten phase III programs, alongside disciplined capital allocation. New launches and acquisitions are set to offset legacy declines, with $250M annualized savings targeted by 2027.